Terms: = Kidney tumors AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
15 results:
1. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
2. Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559.
Verma SK; Biswas A; Kumar M; Mishra A; Choudhury AD; Agrawal S; Sanap SN; Bisen AC; Sharma AK; Panda G; Bhatta RS
Xenobiotica; 2022 May; 52(5):476-487. PubMed ID: 35819259
[TBL] [Abstract] [Full Text] [Related]
3. Dimethoxycurcumin reduces proliferation and induces apoptosis in renal tumor cells more efficiently than demethoxycurcumin and curcumin.
Zanetti TA; Biazi BI; Coatti GC; Baranoski A; Marques LA; Corveloni AC; Mantovani MS
Chem Biol Interact; 2021 Apr; 338():109410. PubMed ID: 33582110
[TBL] [Abstract] [Full Text] [Related]
4. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
[TBL] [Abstract] [Full Text] [Related]
5. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, cyp2d6 phenotype, and OCT2 activity on veliparib pharmacokinetics.
Li J; Kim S; Sha X; Wiegand R; Wu J; LoRusso P
Clin Cancer Res; 2014 Aug; 20(15):3931-44. PubMed ID: 24947923
[TBL] [Abstract] [Full Text] [Related]
6. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and cyp2d6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract] [Full Text] [Related]
7. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract] [Full Text] [Related]
8. Superoxide dismutase and cytochrome P450 isoenzymes might be associated with higher risk of renal cell carcinoma in male patients.
Sverko A; Sobočanec S; Kušić B; Mačak-Šafranko Z; Sarić A; Leniček T; Kraus O; Andrišić L; Korolija M; Balog T; Sunjić SB; Marotti M
Int Immunopharmacol; 2011 Jun; 11(6):639-45. PubMed ID: 21238623
[TBL] [Abstract] [Full Text] [Related]
9. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Gardner ER; Burger H; van Schaik RH; van Oosterom AT; de Bruijn EA; Guetens G; Prenen H; de Jong FA; Baker SD; Bates SE; Figg WD; Verweij J; Sparreboom A; Nooter K
Clin Pharmacol Ther; 2006 Aug; 80(2):192-201. PubMed ID: 16890580
[TBL] [Abstract] [Full Text] [Related]
10. Cytochrome P450 gene polymorphism and cancer.
Agundez JA
Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
[TBL] [Abstract] [Full Text] [Related]
11. Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma.
Gallou C; Longuemaux S; Deloménie C; Méjean A; Martin N; Martinet S; Palais G; Bouvier R; Droz D; Krishnamoorthy R; Junien C; Béroud C; Dupret JM
Pharmacogenetics; 2001 Aug; 11(6):521-35. PubMed ID: 11505222
[TBL] [Abstract] [Full Text] [Related]
12. Detection of anti-LKM-1(anti-cyp2d6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.
Miyakawa H; Kikazawa E; Abe K; Kikuchi K; Fujikawa H; Matsushita M; Kawaguchi N; Morizane T; Ohya K; Kako M
Autoimmunity; 1999; 30(2):107-14. PubMed ID: 10435724
[TBL] [Abstract] [Full Text] [Related]
13. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract] [Full Text] [Related]
14. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.
Webster AR; Richards FM; MacRonald FE; Moore AT; Maher ER
Am J Hum Genet; 1998 Oct; 63(4):1025-35. PubMed ID: 9758595
[TBL] [Abstract] [Full Text] [Related]
15. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract] [Full Text] [Related]
